A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A
in patients with metastatic or unresectable melanoma. Cohorts of patients will receive
escalating doses of DEDN6526A by intravenous infusion on Day 1 of each 21-day cycle. In the
absence of disease progression or unacceptable toxicity, patients may continue to receive
DEDN6552A for up to 17 cycles (1 year).